Hypercalcemia of Malignancy: Time to Pull the Brakes

Area of Science:

• Oncology
• Internal Medicine
• Palliative Care

Background:

• Hypercalcemia of malignancy (HOM) is a common complication in advanced cancers, associated with poor prognosis.
• Limited data exists on HOM outcomes specifically within the Indian population.
• This study addresses the lack of data by examining survival in Indian patients with HOM linked to solid tumors.

Purpose of the Study:

• To describe the survival outcomes of patients with hypercalcemia of malignancy (HOM) associated with solid organ malignancies in India.
• To identify clinical features and prognostic factors influencing survival in this patient cohort.

Main Methods:

• A retrospective study including 45 patients diagnosed with HOM and solid organ malignancies.
• Patients were followed until death, with clinical features and survival data meticulously recorded.
• Statistical analysis focused on overall survival (OS) and mortality rates at 4 and 6 weeks.

Main Results:

• Squamous cell carcinoma of the head and neck and lung cancer were the most frequent primary malignancies associated with HOM.
• The majority of patients presented with poor performance status.
• Median overall survival (OS) was a mere 20 days, with 4-week and 6-week mortality rates at 59.5% and 75.7%, respectively.
• Patients receiving definite anti-cancer therapy had a median OS of 35 days, indicating limited benefit.

Conclusions:

• Hypercalcemia of malignancy in solid tumors is associated with extremely poor survival outcomes.
• The diagnosis of HOM often signifies a terminal stage of cancer.
• Best supportive care, including hospice, should be prioritized over aggressive anti-cancer therapy at this stage.